Kidney Neoplasms Clinical Trial
Official title:
A Phase II Trial of Thalidomide and Capecitabine in Metastatic Renal Cell Carcinoma
The purpose of this study is to determine the efficacy of the combination of thalidomide and capecitabine in metastatic renal cell carcinoma and also to determine the safety of the combination.
n/a
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00678392 -
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
|
Phase 3 | |
| Not yet recruiting |
NCT03129724 -
Retrospective Study in Patients With Metastatic Renal Cancer Treated With TKI Sequence (Tyrosine Kinase Inhibitors of VEGFR) - mTOR- Axitinib Inhibitors or Anti-VEGF Antibody -Inhibiteurs mTOR - Axitinib
|
N/A | |
| Terminated |
NCT01413607 -
The Use of Self Retaining Sutures in Open and Laparoscopic Partial Nephrectomy
|
Phase 4 | |
| Terminated |
NCT00091611 -
Cultured White Cells Plus Interleukin-2 to Treat Advanced Kidney Cancer
|
Phase 1 | |
| Terminated |
NCT02439008 -
Early Biomarkers of Tumor Response in High Dose Hypofractionated Radiotherapy Word Package 3 : Immune Response
|
N/A | |
| Completed |
NCT01688999 -
Cabozantinib for Advanced Urothelial Cancer
|
Phase 2 | |
| Recruiting |
NCT05184504 -
Clinical-pathological Characterization and Outcomes of Renal Cell Carcinoma in Latin American
|
||
| Completed |
NCT04933604 -
LPN in Patients With High-complex Renal Tumors
|
||
| Recruiting |
NCT05068180 -
Low-dose Neuroleptanalgesia for Postoperative Delirium in Elderly Patients
|
Phase 4 | |
| Recruiting |
NCT05119335 -
A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma
|
Phase 1/Phase 2 | |
| Terminated |
NCT02543645 -
A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer
|
Phase 1 | |
| Terminated |
NCT01712685 -
Imaging Studies of Kidney Cancer Using 18F-VM4-037
|
Phase 2 | |
| Terminated |
NCT00816686 -
A Phase 1 Study of the Safety and Pharmacokinetics of AGS-16M18 in Subjects With Advanced Renal Cell Cancer
|
Phase 1 | |
| Completed |
NCT00537056 -
Evaluating Sunitinib Therapy in Renal Cell Carcinoma Using F-18 FDG PET/CT and DCE MRI
|
N/A | |
| Completed |
NCT00076011 -
Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Renal Cell Carcinoma
|
Phase 2 | |
| Terminated |
NCT02900248 -
CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice
|
||
| Recruiting |
NCT03160274 -
Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions
|
||
| Recruiting |
NCT03062410 -
Quality of Life Assessment in Daily Clinical Oncology Practice for Patients With Advanced Renal Cell Carcinoma
|
N/A | |
| Completed |
NCT02924922 -
Assessment of Oncological and Functional Outcomes After Robot Assisted Partial Nephrectomy Versus Laparoscopic Partial Nephrectomy
|
N/A | |
| Terminated |
NCT02386111 -
A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma
|
Phase 1 |